Celecoxib attenuates cachectic events in mice by modulating the expression of vascular endothelial growth factor

Molecular Medicine Reports

Volumn 11, Issue 1, 2015, Pages 289-294

  Xu, Xiaoya ^a   Jiang, Man ^a   Zhang, Ying ^a   Bi, Yuli ^a   Han, Mingyong ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Cancer cachexia; Celecoxib; Cyclooxygenase 2 inhibitor; Vascular Endothelial growth factor

Indexed keywords

BEVACIZUMAB; CELECOXIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; AUTACOID; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; MONOCLONAL ANTIBODY; PYRAZOLE DERIVATIVE; SULFONAMIDE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CACHEXIA; COLON ADENOCARCINOMA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE COUNT; FOOD INTAKE; HEMOGLOBIN DETERMINATION; HISTOPATHOLOGY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; SURVIVAL RATE; THERAPY EFFECT; TUMOR VOLUME; ANEMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; NEOPLASMS; ORGAN SIZE; PATHOLOGY; TUMOR CELL LINE;

MUS;

ANEMIA; ANIMALS; ANTIBODIES, MONOCLONAL; BODY WEIGHT; CACHEXIA; CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; INFLAMMATION MEDIATORS; MALE; MICE; NEOPLASMS; ORGAN SIZE; PYRAZOLES; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84916241591     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2730     Document Type: Article

References (32)

1. Fearon K, Strasser F, Anker SD, et al: Defnition and classifcation of cancer cachexia: an international consensus. Lancet Oncol 12: 489-495, 2011.
2. Kumar NB, Kazi A, Smith T, et al: Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol 11: 107-117, 2010.
3. Donohoe CL, Ryan AM and Reynolds JV: Cancer cachexia: mechanisms and clinical implications. Gastroenterol Res Pract 2011: 601434, 2011.
4. Argilés JM, Busquets S, Toledo M and López-Soriano FJ: The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care 3: 263-268, 2009
5. Gupta SC, Kim JH, Kannappan R, et al: Role of nuclear factor KB-mediated infammatory pathways in cancer-related symptoms and their regulation by nutritional agents. Exp Biol Med (Maywood) 236: 658-671, 2011.
6. Claria J: Publication of a special issue: resolution of acute inflammation and the role of lipid mediators. Scientifc World Journal 10: 1553-1555, 2010.
7. Tan BH, Ross JA, Kaasa S, et al; European Palliative Care Research Collaborative: Identifcation of possible genetic polymorphisms involved in cancer cachexia: a systematic review. J Genet 90: 165-177, 2011.
8. Argilés JM, Busquets S and López-Soriano FJ: Anti-infammatory therapies in cancer cachexia. Eur J Pharmacol 668 (Suppl 1): S81-S86, 2011.
9. Batista ML Jr, Peres SB, McDonald ME, et al: Adipose tissue infammation and cancer cachexia: possible role of nuclear transcription factors. Cytokine 57: 9-16, 2012.
10. Thiel A, Mrena J and Ristimäki A: Cyclooxygenase-2 and gastric cancer. Cancer Metastasis Rev 30: 387-395, 2011.
11. Turk HM, Camci C, Sevinc A, et al: Cyclooxygenase-2 expression is not a marker of poor survival in lung cancer. Asian Pac J Cancer Prev 13: 315-318, 2012.
12. Williams CS, Mann M and DuBois RN: The role of cyclooxy-genases in infammation, cancer and development. Oncogene 187908-7916, 1999
13. Morita Y, Hata K, Nakanishi M, et al: Cyclooxygenase-2 promotes tumor lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma. Int J Oncol, 41: 885-892, 2012.
14. Xin X, Majumder M, Girish GV, et al: Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Invest 92: 1115-1128, 2012.
15. Tisdale MJ: Cachexia in cancer patients. Nat Rev Cancer 2: 862-871, 2002.
16. Davis T W, Zweifel BS, O'Neal JM, et al: Inhibition of cyclo-oxygenase-2 by celecoxib reverses tumor-induced wasting. J Pharmacol Exp Ther 308: 929-934, 2004.
17. Yang SY, Yu H, Krygier JE, Wooley PH and Mott MP: High VEGF with rapid growth and early metastasis in mouse osteo-sarcoma model. Sarcoma 2007: 95628, 2007.
18. Evans WJ, Morley JE, Argilés J, et al: Cachexia: a new defnition. Clin Nutr 27: 793-799, 2008.
19. Serhan CN, Krishnamoorthy S, Recchiuti A and Chiang N: Novel anti-infammatory-pro-resolving mediators and their receptors. Curr Top Med Chem 11: 629-647, 2011.
20. Zhao QT, Yue SQ, Cui Z, et al: Potential involvement of the cyclo-oxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis. Life Sci 80: 484-492, 2007.
21. Seelaender M, Batista M Jr, Lira F, Silverio R and Rossi-Fanelli F: Infammation in cancer cachexia: to resolve or not to resolve (is that the question?). Clin Nutr 31: 562-566, 2012.
22. Argilés JM, López-Soriano FJ and Busquets S: Mechanisms to explain wasting of muscle and fat in cancer cachexia. Curr Opin Support Palliat Care 1: 293-298, 2007.
23. Lawrence T and Fong C: The resolution of inflammation: anti-inflammatory roles for NF-kappaB. Int J Biochem Cell Biol 42: 519-523, 2010.
24. Patra SK and Arora S: Integrative role of neuropeptides and cytokines in cancer anorexia-cachexia syndrome. Clin Chim Acta 413: 1025-1034, 2012.
25. Laviano A, Molfno A, Seelaender M, et al: Carnitine administration reduces cytokine levels, improves food intake, and ameliorates body composition in tumor-bearing rats. Cancer Invest 29: 696-700, 2011.
26. Weidle UH, Klostermann S, Eggle D and Krüger A: Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer. Cancer Genomics Proteomics 7: 287-302, 2010.
27. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
28. Shojaei F and Ferrara N: Antiangiogenesis to treat cancer and intraocular neovascular disorders. Lab Invest 87: 227-230, 2007.
29. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, et al: Acute-phase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancers. Clin Chem Lab Med 46: 359-364, 2008.
30. Kemik O, Sumer A, Kemik AS, et al: The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer. World J Surg Oncol 8: 85, 2010.
31. Valcárcel M, Mendoza L, Hernández JJ, et al: Vascular endo-thelial growth factor regulates melanoma cell adhesion and growth in the bone marrow microenvironment via tumor cyclo-oxygenase-2. J Transl Med 9: 142, 2011.
32. Kim YY, Lee EJ, Kim YK, et al: Anti-cancer effects of celecoxib in head and neck carcinoma. Mol Cells 29: 185-194, 2010.